MylaPLai-GoldmanMD
Pathology • Burlington, VTAnatomic Pathology, Clinical Pathology
Co-Founder and Chairperson, GeneCentric Therapeutics
Dr. Lai-Goldman is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
C/o Personalized Science, LLC
Burlington, VT 05403- Is this information wrong?
Education & Training
UCLA David Geffen School of Medicine/UCLA Medical CenterFellowship, Hematology and Medical Oncology, 1988 - 1989- UCLA David Geffen School of Medicine/UCLA Medical CenterResidency, Pathology-Anatomic and Clinical, 1984 - 1988
Icahn School of Medicine at Mount Sinai/Morningside/WestInternship, Internal Medicine, 1983 - 1984
Columbia University Vagelos College of Physicians and SurgeonsClass of 1983
Certifications & Licensure
CA State Medical License 1985 - 2022
NC State Medical License 1990 - 2021
NJ State Medical License 2003 - 2009- American Board of Pathology Anatomic Pathology & Clinical Pathology
Publications & Presentations
PubMed
- 115 citationsLung Adenocarcinoma and Squamous Cell Carcinoma Gene Expression Subtypes Demonstrate Significant Differences in Tumor Immune LandscapeHawazin Faruki, Gregory Mayhew, Jonathan S. Serody, D. Neil Hayes, Charles M. Perou, Myla Lai-Goldman> ;Journal of Thoracic Oncology. 2017 Jun 1
- 4 citationsValidation of the Lung Subtyping Panel in Multiple Fresh-Frozen and Formalin-Fixed, Paraffin-Embedded Lung Tumor Gene Expression Data SetsHawazin Faruki, Gregory Mayhew, Cheng Fan, Matthew D. Wilkerson, Scott Parker, Lauren Kam-Morgan, Marcia Eisenberg, Bruce Horten, D. Neil Hayes, Charles M. Perou, Myla...> ;Archives of Pathology & Laboratory Medicine. 2016 Jun 1
- 13 citationsApplication of a pharmacogenetic test adoption model to six oncology biomarkers.Hawazin Faruki, Myla Lai-Goldman> ;Personalized Medicine. 2010 Jul 5
- Join now to see all
Press Mentions
Precision Cancer Drug Startup GeneCentric Acquires Nearby Select ImmunoGenomicsAugust 26th, 2019- RTP-Based GeneCentric Therapeutics Seeks Better Diagnostic Test for Head, Neck CancerAugust 19th, 2019
GeneCentric Therapeutics Acquires Select ImmunoGenomicsAugust 15th, 2019- Join now to see all
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
